Literature DB >> 21440677

Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome.

Dimitry Migdalovich1, Arthur J Moss, Coeli M Lopes, Jason Costa, Gregory Ouellet, Alon Barsheshet, Scott McNitt, Slava Polonsky, Jennifer L Robinson, Wojciech Zareba, Michael J Ackerman, Jesaia Benhorin, Elizabeth S Kaufman, Pyotr G Platonov, Wataru Shimizu, Jeffrey A Towbin, G Michael Vincent, Arthur A M Wilde, Ilan Goldenberg.   

Abstract

BACKGROUND: Men and women with type 2 long QT syndrome (LQT2) exhibit time-dependent differences in the risk for cardiac events. We hypothesized that data regarding the location of the disease-causing mutation in the KCNH2 channel may affect gender-specific risk in LQT2.
OBJECTIVE: This study sought to risk-stratify LQT2 patients for life-threatening cardiac events based on clinical and genetic information.
METHODS: The risk for life-threatening cardiac events from birth through age 40 years (comprising aborted cardiac arrest [ACA] or sudden cardiac death [SCD]) was assessed among 1,166 LQT2 male (n = 490) and female (n = 676) patients by the location of the LQTS-causing mutation in the KCNH2 channel (prespecified in the primary analysis as pore-loop vs. non-pore-loop).
RESULTS: During follow-up, the cumulative probability of life-threatening cardiac events years was significantly higher among LQT2 women (26%) as compared with men (14%; P <.001). Multivariate analysis showed that the risk for life-threatening cardiac events was not significantly different between women with and without pore-loop mutations (hazard ratio 1.20; P =.33). In contrast, men with pore-loop mutations displayed a significant >2-fold higher risk of a first ACA or SCD as compared with those with non-pore-loop mutations (hazard ratio 2.18; P = .01). Consistently, women experienced a high rate of life-threatening events regardless of mutation location (pore-loop: 35%, non-pore-loop: 23%), whereas in men the rate of ACA or SCD was high among those with pore-loop mutations (28%) and relatively low among those with non-pore-loop mutations (8%).
CONCLUSION: Combined assessment of clinical and mutation-specific data can be used for improved risk stratification for life-threatening cardiac events in LQT2.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440677      PMCID: PMC4028036          DOI: 10.1016/j.hrthm.2011.03.049

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  15 in total

1.  Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones.

Authors:  M Song; G Helguera; M Eghbali; N Zhu; M M Zarei; R Olcese; L Toro; E Stefani
Journal:  J Biol Chem       Date:  2001-06-26       Impact factor: 5.157

Review 2.  HERG1 channelopathies.

Authors:  Michael C Sanguinetti
Journal:  Pflugers Arch       Date:  2009-11-22       Impact factor: 3.657

3.  Modulation by testosterone of an endogenous hERG potassium channel current.

Authors:  J M Ridley; Y M Shuba; A F James; J C Hancox
Journal:  J Physiol Pharmacol       Date:  2008-09       Impact factor: 3.011

Review 4.  Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.

Authors:  C T January; Q Gong; Z Zhou
Journal:  J Cardiovasc Electrophysiol       Date:  2000-12

5.  Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.

Authors:  I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

6.  Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone.

Authors:  H Bidoggia; J P Maciel; N Capalozza; S Mosca; E J Blaksley; E Valverde; G Bertran; P Arini; M O Biagetti; R A Quinteiro
Journal:  Am Heart J       Date:  2000-10       Impact factor: 4.749

7.  Long QT syndrome: from channels to cardiac arrhythmias.

Authors:  Arthur J Moss; Robert S Kass
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  Genotype-phenotype aspects of type 2 long QT syndrome.

Authors:  Wataru Shimizu; Arthur J Moss; Arthur A M Wilde; Jeffrey A Towbin; Michael J Ackerman; Craig T January; David J Tester; Wojciech Zareba; Jennifer L Robinson; Ming Qi; G Michael Vincent; Elizabeth S Kaufman; Nynke Hofman; Takashi Noda; Shiro Kamakura; Yoshihiro Miyamoto; Samit Shah; Vinit Amin; Ilan Goldenberg; Mark L Andrews; Scott McNitt
Journal:  J Am Coll Cardiol       Date:  2009-11-24       Impact factor: 24.094

Review 9.  Long QT Syndrome.

Authors:  Ilan Goldenberg; Wojciech Zareba; Arthur J Moss
Journal:  Curr Probl Cardiol       Date:  2008-11       Impact factor: 5.200

Review 10.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

View more
  29 in total

1.  Atrial Fibrillation in Long QT Syndrome by Genotype.

Authors:  Pyotr G Platonov; Scott McNitt; Bronislava Polonsky; Spencer Z Rosero; Wojciech Zareba
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-10-15

Review 2.  Genotype-specific risk stratification and management of patients with long QT syndrome.

Authors:  Alon Barsheshet; Olena Dotsenko; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-11-08       Impact factor: 1.468

Review 3.  How do sex hormones modify arrhythmogenesis in long QT syndrome? Sex hormone effects on arrhythmogenic substrate and triggered activity.

Authors:  Katja E Odening; Gideon Koren
Journal:  Heart Rhythm       Date:  2014-06-19       Impact factor: 6.343

Review 4.  Inherited arrhythmia syndromes leading to sudden cardiac death in the young: a global update and an Indian perspective.

Authors:  Priya Chockalingam; Arthur A Wilde
Journal:  Indian Heart J       Date:  2013-12-17

Review 5.  Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives.

Authors:  Saagar Mahida; Andrew J Hogarth; Campbell Cowan; Muzahir H Tayebjee; Lee N Graham; Christopher B Pepper
Journal:  J Interv Card Electrophysiol       Date:  2013-03-21       Impact factor: 1.900

6.  Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications.

Authors:  David S Auerbach; Yitschak Biton; Bronislava Polonsky; Scott McNitt; Robert A Gross; Robert T Dirksen; Arthur J Moss
Journal:  Transl Res       Date:  2017-10-20       Impact factor: 7.012

7.  Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.

Authors:  Sven Zumhagen; Birgit Stallmeyer; Corinna Friedrich; Lars Eckardt; Guiscard Seebohm; Eric Schulze-Bahr
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-21

8.  Ion Channel Diseases: an Update for 2016.

Authors:  Gordon F Tomaselli; Andreas S Barth
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

9.  For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death.

Authors:  Ivaylo Tonchev; David Luria; David Orenstein; Chaim Lotan; Yitschak Biton
Journal:  Curr Cardiol Rep       Date:  2019-08-02       Impact factor: 2.931

10.  "QT clock" to improve detection of QT prolongation in long QT syndrome patients.

Authors:  Alex Page; Mehmet K Aktas; Tolga Soyata; Wojciech Zareba; Jean-Philippe Couderc
Journal:  Heart Rhythm       Date:  2015-08-31       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.